Acquisition of own shares
Brussels (Belgium), 24 June 2014 – 18:30 (CET) – regulated information
In application of article 207 of the Royal Decree executing the Companies Code, UCB SA/NV announces the below.
On 20 June 2014, UCB SA/NV sold 725,000 UCB shares OTC to a bank counterparty for settlement on 25 June 2014 at a price of € 61.7817 per share. In combination with this spot transaction, also on 20 June 2014, UCB SA/NV repurchased 725,000 USB shares OTC from the same counterparty for settlement on 27 April 2015 (subject to the exercise by UCB SA/NV of its early termination right in accordance with and pursuant to the underlying bilateral documentation), at the same price per share, together a share swap transaction. The highest independent bid price on Euronext Brussels on 20 June 2014 was € 61.99.
Furthermore, on 20 June 2014, UCB SA/NV sold 725,000 UCB shares OTC to another bank counterparty for settlement on 25 June 2014 at a price of € 61.7817 per share. In combination with this spot transaction, also on 20 June 2014, UCB SA/NV repurchased 725,000 UCB shares OTC from the same counterparty for settlement on 27 April 2015 (subject to the exercise by UCB SA/NV of its early termination right in accordance with and pursuant to the underlying bilateral documentation), at the same price per share, together a share swap transaction. The highest independent bid price on Euronext Brussels on 20 June 2014 was € 61.99.
UCB SA/NV owns, on 20 June 2014, 307,401 UCB shares, which represent 0.16% of the total number of shares issued by the company (194,505,658).
An up-to-date overview of the UCB SA/NV large shareholdings is included in the corporate governance charter of UCB SA/NV, which is published on UCB SA/NV’s website.
For further information
- Antje Witte, Investor Relations UCB
T +32.2.559.9414, firstname.lastname@example.org
- Alexandra Deschner, Investor Relations, UCB
T +32 2 559 9683, email@example.com
- France Nivelle, Global Communications UCB
T +32.2.559.9178, firstname.lastname@example.org
- Laurent Schots, Media Relations, UCB
T +32.2.559.9264, email@example.com
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8700 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
Stay up-to-date on the latest news and information from UCB